Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncologic Committee To Meet Nov. 8 On Accelerated Approval Commitments

This article was originally published in The Pink Sheet Daily

Executive Summary

Committee to revisit drugs with postmarketing commitments previously reviewed in 2003 and give advice for conduct of confirmatory studies for sponsors with newly approved drugs.

You may also be interested in...



Submitted Data Confirm Doxil's Clinical Benefit, J&J Maintains

FDA's Oncologic Drugs Advisory Committee will review on Nov. 8 unfulfilled accelerated approval trial commitments for products approved before 2002.

Submitted Data Confirm Doxil's Clinical Benefit, J&J Maintains

FDA's Oncologic Drugs Advisory Committee will review on Nov. 8 unfulfilled accelerated approval trial commitments for products approved before 2002.

MedImmune Expands Oncology Pipeline With Therapeutic Protein Technology

Agreement with Avidia is firm's eleventh licensing deal or acquisition of validated targets for product development in the last 12 months.

Related Content

Topics

UsernamePublicRestriction

Register

PS061228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel